ENTRY       D12407                      Drug
NAME        Eladocagene exuparvovec (USAN/INN);
            Upstaza (TN)
EFFICACY    Nervous system disease agent
  TYPE      Gene therapy product
COMMENT     Recombinant AAV2 vector containing the human cDNA for the DDC geneTreatment of AADC deficiency
TARGET      DDC* [HSA_VAR:1644v1] [HSA:1644] [KO:K01593]
  PATHWAY   hsa00350(1644)  Tyrosine metabolism
            hsa00380(1644)  Tryptophan metabolism
BRITE       Target-based classification of drugs [BR:br08310]
             Enzymes
              Lyases (EC4)
               Carboxy-lyases
                DDC* [HSA_VAR:1644v1]
                 D12407  Eladocagene exuparvovec (USAN/INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12407
             Cellular and gene therapy products
              D12407
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12407
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D12407
DBLINKS     CAS: 2098615-91-7
///
